We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Screening Technique Finds Endothelial Cells Targeted by Nanoparticles

By LabMedica International staff writers
Posted on 18 Oct 2018
A recently developed technique allows researchers to identify lipid nanoparticles that preferentially target endothelial cells – rather than liver cells – for transport of the components of the CRISPR/Cas9 gene-editing tool.

Nanoparticle-mediated delivery of siRNA to hepatocytes has been used to treat disease in humans. More...
However, systemically delivering RNA drugs to tissues other than the liver has remained an important challenge, primarily because there is no high-throughput method to identify nanoparticles that deliver functional mRNA to cells in vivo.

To increase the number of nanoparticles that could be studied in vivo, investigators at the Georgia Institute of Technology (Atlanta, USA) designed a high-throughput method for which they coined the name FIND (Fast Identification of Nanoparticle Delivery). This method is capable of quantifying how more than 100 lipid nanoparticles (LNPs) deliver mRNA that is translated into functional protein.

To prepare the nanoparticles nucleic acids (mRNA, DNA barcodes, siRNA, and sgRNA) were diluted in citrate buffer while lipid-amine compounds, alkyl-tailed PEG, cholesterol, and helper lipids were diluted in ethanol. The nanoparticles were generated by combining the citrate and ethanol phases by syringes in a microfluidic device.

The FIND technique also introduced a red-colored tracer protein (Cre) into cells. This was done by co-delivering Cas9 mRNA and single-guide RNA, which induced endothelial cell gene editing.

The investigators reported in the October 1, 2018, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America that they had measured how more than 250 LNPs were able to deliver mRNA to multiple cell types in vivo and identified two LNPs that efficiently delivered siRNA, single-guide RNA (sgRNA), and mRNA to endothelial cells. One of the nanoparticles delivered Cas9 mRNA and sgRNA to splenic endothelial cells as efficiently as hepatocytes, distinguishing it from LNPs that delivered Cas9 mRNA and sgRNA to hepatocytes more than other cell types.

"We hope to take projects that would ordinarily require years and complete several of them within the next 12 months," said senior author Dr. James E. Dahlman, assistant professor of biomedical engineering at the Georgia Institute of Technology. "FIND could be used to carry all sorts of nucleic acid drugs into cells. That could include small RNAs, large RNAs, small DNAs and large DNAs - many different types of genetic drugs that are now being developed in research labs."

Related Links:
Georgia Institute of Technology


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.